Danish pharmaceutical company Novo Nordisk A/S (NVO) said Monday that the US Food and Drug Administration issued a Refusal to File letter covering the label expansion application for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes which was filed on 20 January 2021.
In the letter, FDA has requested additional information including data relating to a proposed new manufacturing site.
Additional information needs to be included in the resubmission. But the company believes the already completed clinical trial program will be sufficient for approval of the label expansion application.
The company expects to resubmit the application to FDA during the second quarter of 2021.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.